drugset / Trial / NCT04750941
Study of Copanlisib and Ketogenic Diet
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a multicenter, open label, pilot phase II study of the PI3K inhibitor copanlisib in combination with a ketogenic diet in the treatment of patients with one of the following malignancies: (a) relapsed or refractory (R/R) follicular lymphoma (FL), (b) R/R endometrial cancer (EC) with a documented activating mutation in PIK3CA or loss of phosphatase and tensin homolog (PTEN).
Timeline
- Start
- 2022-02-10
- Primary completion
- 2023-06-09
- Completion
- 2023-06-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Copanlisib | Small molecule | — | Intravenous |